<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2301233143
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Uxorate
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FEBUXOSTAT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        84.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="(Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            (Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 437]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M04AA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Uxorate film coated tablets contain the active substance febuxostat and are used to treat gout, which is associated with an excess of a chemical called uric acid (urate) in the body. In some people, the amount of uric acid builds up in the blood and may become too high to remain soluble. When this happens, urate crystals may form in and around the joints and kidneys. These crystals can cause sudden, severe pain, redness, warmth and swelling in a joint (known as a gout attack). Left untreated, larger deposits called tophi may form in and around joints. These tophi may cause joint and bone damage. Uxorate works by reducing uric acid levels. Keeping uric acid levels low by taking Uxorate once every day stops crystals building up, and over time it reduces symptoms. Keeping uric acid levels sufficiently low for a long enough period can also shrink tophi. Uxorate is for adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Uxorate film coated tablets: - if you are allergic to Febuxostat or any of the other ingredients of this medicine (listed in section 6) Warnings and precautions Talk to your doctor or pharmacist before taking Uxorate film coated tablets: Talk to your doctor before taking Uxorate: - If you have or have had heart failure, heart problems or stroke - If you have or have had renal disease and/or serious allergic reaction to Allopurinol (a medication used for the treatment of Gout) - If you have or have had liver disease or liver function test abnormalities - If you are being treated for high uric acid levels as a result of LeschNyhan syndrome (a rare inherited condition in which there is too much uric acid in the blood) - If you have thyroid problems. - Should you experience allergic reactions to UXORATE, stop taking this medicine (see also section 4). Possible symptoms of allergic reactions might be: - rash including severe forms (e.g., blisters, nodules, itchy-, exfoliative rash), itchiness - swelling of limbs or face - difficulties in breathing - fever with enlarged lymph nodes - but also, serious life-threatening allergic conditions with cardiac and circulatory arrest. Your doctor might decide to permanently stop treatment with Uxorate. There have been rare reports of potentially life-threatening skin rashes (Stevens-Johnson Syndrome) with the use of UXORATE, appearing initially as reddish target-like spots or circular patches often with central blister on the trunk. It may also include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). The rash may progress to widespread blistering or peeling of the skin. If you have developed Stevens-Johnson Syndrome with the use of febuxostat, you must not be re-started on Uxorate at any time. If you develop a rash or these skin symptoms, seek immediate advice from a doctor and tell that you are taking this medicine. If you are having a gout attack at the moment (a sudden onset of severe pain, tenderness, redness, warmth and swelling in a joint), wait for the gout attack to subside before first starting treatment with UXORATE. For some people, gout attacks may flare up when starting certain medicines that control uric acid levels. Not everyone gets flares, but you could get a flare-up even if you are taking UXORATE, and especially during the first weeks or months of treatment. It is important to keep taking UXORATE even if you have a flare, as UXORATE is still working to lower uric acid. Over time, gout flares will occur less often and be less painful if you keep taking UXORATE every day. Your doctor will often prescribe other medicines, if they are needed, to help prevent or treat the symptoms of flares (such as pain and swelling in a joint). Your doctor may ask you to have blood tests to check that your liver is working normally. Children Do not give this medicine to children under the age of 18 because the safety and efficacy have not been established. Other medicines and Uxorate film coated tablets Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. It is especially important to tell your doctor or pharmacist if you are taking medicines containing any of the following substances as they may interact with Uxorate and your doctor may wish to consider necessary measures: - Mercaptopurine (used to treat cancer) - Azathioprine (used to reduce immune response) - Theophylline (used to treat asthma) Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Taking Uxorate with food and drink: The tablets should be taken by mouth and can be taken with or without food. Pregnancy and Breast-feeding It is not known if Uxorate may harm your unborn child. Uxorate should not be used during pregnancy. It is not known if Uxorate may pass into human breast milk. You should not use Uxorate if you are breast feeding, or if you are planning to breastfeed. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines Be aware that you may experience dizziness, sleepiness, blurred vision and numbness or tingling sensation during treatment and should not drive or operate machines if affected. Uxorate film coated tablets contains lactose Uxorate film coated tablets contain lactose (a type of sugar). If you have been told that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. Check with your doctor or pharmacist if you are not sure. &bull; The usual dose is one tablet daily. The back of the blister pack is marked with the days of the week to help you check that you have taken a dose each day. &bull; The tablets should be taken by mouth and can be taken with or without food. Gout Uxorate is available in 40mg, 80 mg tablet or a 120 mg tablet. Your doctor will have prescribed the strength most suitable for you. Continue to take Uxorate every day even when you are not experiencing gout flare or attack. The score line on the 80 mg tablets is only to facilitate breaking for ease of swallowing and not to divide into equal doses. If you take more Uxorate film coated tablets than you should In the event of an accidental overdose ask your doctor what to do or contact your nearest accident and emergency department. If you forget to take Uxorate film coated tablets If you miss a dose of Uxorate take it as soon as you remember unless it is almost time for your next dose, in which case miss out the forgotten dose and take your next dose at the normal time. Do not take a double dose to make up for a forgotten dose. If you stop taking Uxorate film coated tablets Do not stop taking UXORATE without the advice of your doctor even if you feel better. If you stop taking UXORATE your uric acid levels may begin to rise, and your symptoms may worsen due to the formation of new crystals of urate in and around your joints and kidneys. If you have any further questions on the use of this medicine, ask your doctor, nurse, or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop taking this medicine and contact your doctor immediately or go to an emergency department nearby if the following rare (may affect up to 1 in 1,000 people) side effects occur, because a serious allergic reaction might follow: &bull; anaphylactic reactions, drug hypersensitivity (see also section 2 &ldquo;Warnings and precautions&rdquo;) &bull; potentially life-threatening skin rashes characterised by formation of blisters and shedding of the skin and inner surfaces of body cavities, e.g. mouth and genitals, painful ulcers in the mouth and/or genital areas, accompanied by fever, sore throat and fatigue (StevensJohnson Syndrome/ Toxic Epidermal Necrolysis), or by enlarged lymph nodes, liver enlargement, hepatitis (up to liver failure), raising of the white-cells count in the blood (drug reaction with eosinophilia and systemic symptoms-DRESS) (see section 2) &bull; generalised skin rashes &bull; The common side effects (may affect up to 1 in 10 people) are: &bull; abnormal liver test results &bull; diarrhoea &bull; headache &bull; rash (including various types of rashes, please see below under &ldquo;uncommon&rdquo; and &ldquo;rare&rdquo; sections) &bull; nausea &bull; increase in gout symptoms &bull; localised swelling due to retention of fluids in tissues (oedema) &bull; Other side effects which are not mentioned above are listed below. &bull; Uncommon side effects (may affect up to 1 in 100 people) are: &bull; decreased appetite, change in blood sugar levels (diabetes) of which a symptom may be excessive thirst, increased blood fat levels, weight increase &bull; loss of sex drive &bull; difficulty in sleeping, sleepiness &bull; dizziness, numbness, tingling, reduced or altered sensation (hypoaesthesia, hemiparesis or paraesthesia), altered sense of taste, diminished sense of smell (hyposmia) &bull; abnormal ECG heart tracing, irregular, or rapid heartbeats, feeling your heartbeat (palpitation) &bull; hot flushes or flushing (e.g., redness of the face or neck), increased blood pressure. &bull; cough, shortness of breath, chest discomfort or pain, inflammation of nasal passage and/or throat (upper respiratory tract infection), bronchitis &bull; dry mouth, abdominal pain/discomfort or wind, heartburn/indigestion, constipation, more frequent passing of stools, vomiting, stomach discomfort &bull; itching, hives, skin inflammation, skin discoloration, small red or purple spots on the skin, small, flat red spots on the skin, flat, red area on the skin that is covered with small confluent bumps, rash, areas of redness and spots on the skin, other type of skin conditions &bull; muscle cramp, muscle weakness, pain/ache in muscles/joints, bursitis, or arthritis (inflammation of joints usually accompanied by pain, swelling and/or stiffness), pain in extremity, back pain, muscle spasm &bull; blood in the urine, abnormal frequent urination, abnormal urine tests (increased level of proteins in the urine), a reduction in the ability of the kidneys to function properly &bull; fatigue, localised swelling due to the retention of fluids in the tissues (oedema), chest pain, chest discomfort &bull; stones in the gallbladder or in bile ducts (cholelithiasis) &bull; increase in blood thyroid stimulating hormone (TSH) level &bull; changes in blood chemistry or amount of blood cells or platelets (abnormal blood test results) &bull; kidney stones &bull; erectile difficulties &bull; Rare side effects (may affect up to 1 in 1,000 people) are: &bull; muscle damage, a condition which on rare occasions can be serious. It may cause muscle problems and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown. Contact your doctor immediately if you experience muscle pain, tenderness, or weakness &bull; severe swelling of the deeper layers of the skin, especially around the lips, eyes, genitals, hands, feet, or tongue, with possible sudden difficult breathing &bull; high fever in combination with measles-like skin rash, enlarged lymph nodes, liver enlargement, hepatitis (up to liver failure), raising of the white-cells count in the blood (leukocytosis, with or without eosinophilia) &bull; reddening of the skin (erythema), rash in various types (e.g., itchy, with white spots, with blisters, with blisters containing pus, with shedding of the skin, measles-like rash), widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes, resulting in exfoliation and possible sepsis (StevensJohnson Syndrome/Toxic epidermal necrolysis) &bull; nervousness &bull; feeling thirsty &bull; ringing in the ears &bull; blurred vision, change in vision &bull; hair loss &bull; mouth ulceration &bull; inflammation of the pancreas: common symptoms are abdominal pain, nausea and vomiting &bull; increased sweating &bull; weight decrease, increased appetite, uncontrolled loss of appetite (anorexia) &bull; muscle and/or joint stiffness &bull; abnormally low blood cell counts (white or red blood cells or platelets) &bull; urgent need to urinate &bull; changes or decrease in urine amount due to inflammation in the kidneys (tubulointerstitial nephritis) &bull; inflammation of the liver (hepatitis) &bull; yellowing of the skin (jaundice) &bull; liver damage &bull; increased level of creatine phosphokinase in blood (an indicator of muscle damage) &bull; sudden cardiac death Reporting of side effects If you get any side effects, talk to your doctor, nurse, or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children. &bull; Do not use this medicine after the expiry date which is stated on the carton and label after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month. &bull; Store below 30&deg; C. &bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is: Febuxostat The other ingredients are: Microcrystalline Cellulose, Lactose Monohydrate, Croscarmellose Sodium, Hydroxypropyl Cellulose, Colloidal silicon dioxide, Opadry II Yellow and Magnesium Stearate..</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                - 40 mg film coated tablets are: Yellow, round, biconvex, film coated 
tablet with “C1” on one side and plain on the other side.
- 80 mg film coated tablets are: Yellow, Capsule shaped, biconvex, 
film coated tablet plain on one side and breakline on the other side.
- 120 mg film coated tablets are: Yellow, Capsule shaped, biconvex, 
film coated tablet debossed with “C64” on one side and ‘/’ on the 
other side.
Uxorate film coated tablets are available in 40mg- 3 blisters (10 
tablets / blister), 80mg- 2 blisters (14 tablets / blister) and 120mg- 2 
blisters (14 tablets / blister).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Middle East Pharmaceutical Industries Co Ltd (Avalon Pharma) P.O.Box 4180 Riyadh 11491 2nd Industrial City, Riyadh, Kingdom of Saudi Arabia Tel: +966 (11) 2653948 -2653427 Fax: +966 (11) 2654723</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was approved in [11/2022]
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تحتوي أقراص يوكسورات المغلفة على المادة الفعالة فيبوكسوستات وت النقرس، و هي حاالت تنجم عن حدوث زيادة في تركيز مادة كيميائية تسمى حمض اليوريك )اليورات( في حاالت الجسم. في بعض األفراد تتراكم كمية حمض اليوريك ًّ في الدم، وقد تصبح مرتفعة جدا بحيث ال تبقى قابلة للذوبان. وعندحدوث ذلك قد تتشكل بلورات اليورات بداخل وحول المفاصل والكلى. قد تسبب هذه البلورات بشكل مفاجئ؛ حدوث ألم شديد، احمرار، حرارة وتورم في المفصل )المعروف باسم نوبة النقرس(. ُركت دون عالج. قد َوف بداخل المفاصل وحولها إذا ت ُ قد تتشكل رواسب أكبر تسمى ت َوف في تلف المفاصل والعظام. ُ تتسبب هذه الت يعمل يوكسورات على تقليل مستويات حمض اليوريك. إن الحفاظ على مستويات حمض اليوريك منخفضة عن طريق تناول يوكسورات مرة واحدة يوميًّا سيوقف تراكم البلورات، وستقل األعراض مع مرور الوقت. كما أن الحفاظ على مستويات حمض ُوف. ُ اليوريك منخفضة بدرجة كافية لفترة كافية سيؤدي إلى تقلص الت يتم إعطاء يوكسورات للبالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ال تتناول أقراص يوكسورات المغلفة: ٍ من المكونات األخرى لهذا الدواء ّ إذا كانت لديك حساسية تجاه فيبوكسوستات أو أي ُ )المدرجة في القسم 6(. تحذيرات واحتياطات ِ استش ُ ر طبيبك أو الصيدلي قبل أن تتناول أقراص يوكسورات المغلفة: - إذا كنت تعاني أو سبق أن عانيت من قصور في القلب أو مشاكل في القلب أو سكتة دماغية. - إذا كنت تعاني أو سبق أن عانيت من مرض كلوي و / أو رد فعل تحسسي خطير ُستخدم لعالج النقرس(. أللوبيورينول )دواء ي - إذا كنت تعاني أو سبق أن عانيت من أمراض الكبد أو اضطرابات في اختبار وظائف الكبد. ُعالج من ارتفاع مستويات حمض اليوريك نتيجة لمتالزمة ليش نيهان )حالة - إذا كنت ت وراثية نادرة حيث يوجد الكثير من حمض اليوريك في الدم(. - إذا كنت تعاني من مشاكل في الغدة الدرقية. ً - إذا كنت تعاني من حساسية تجاه يوكسورات فتوقف عن تناول هذا الدواء )انظر أيضا لقسم 4(. قد تكون األعراض المحتملة لردود الفعل التحسسية ما يلي: - طفح جلدي بما في ذلك األشكال الشديدة، على سبيل المثال: )بثور، العقيدات، طفح جلدي مثير للحكة، طفح جلدي تقشيري(، الحكة. - تورم في األطراف أو الوجه. - صعوبات في التنفس. - حمى مع تضخم الغدد الليمفاوية. ً - ولكن أيضا حاالت حساسية خطيرة مهددة للحياة مع السكتة الدماغية وتوقف الدورة الدموية. قد يقرر طبيبك إيقاف العالج باستخدام يوكسورات بشكل دائم. ُحتمل أن يهدد الحياة )متالزمة كانت هناك تقارير نادرة عن ظهور طفح جلدي ي ستيفنز جونسون( عند استخدام يوكسورات، ويظهر في البداية على هيئة بقع حمراء شبيهة بالهدف أو بقع دائرية تقترن عادة ببثور وسطية على المؤخرة. كما قد تشمل تقرحات في الفم والحلق واألنف واألعضاء التناسلية والتهاب الملتحمة )العينين الحمراء والمنتفخة(. قد يتطور الطفح الجلدي إلى تقرحات واسعة االنتشار أو تقشير بالجلد. إذا كنت قد أصبت بمتالزمة ستيفنز جونسون عند استخدام فيبوكسوستات، فال يجب إعادة بدء العالج بيوكسورات في أي وقت. إذا أصبت بطفح جلدي أو هذه األعراض الجلدية، اطلب المشورة الفورية من الطبيب وأخبره أنك تتناول هذا الدواء. إذا كنت تعاني من نوبة النقرس في هذه اللحظة )ظهور مفاجئ لأللم الشديد وليونة واحمرار ودفء وتورم في المفصل(، انتظر حتى تهدأ نوبة النقرس قبل البدء في العالج باستخدام يوكسورات. بالنسبة لبعض األشخاص قد تظهر لديهم نوبات نقرس شديدة عند بدء استخدام بعض األدوية التي تتحكم في مستويات حمض اليوريك. ال تظهر تلك النوبات الشديدة لدى ُصاب بتلك النوبات الشديدة حتى لو كنت تتناول يوكسورات، وخاصة الجميع، ولكن قد ت خالل األسابيع أو األشهر األولى من العالج. من المهم المواظبة على تناول يوكسورات حتى عند حدوث تلك النوبات الشديدة، حيث ال يزال يوكسورات يعمل على خفض حمض اليوريك. مع مرور الوقت سيقل حدوث ً نوبات النقرس الشديدة، وستكون أقل ألما إذا واظبت على تناول يوكسورات كل يوم. ًا ما يصف طبيبك أدوية أخرى إذا كانت هناك حاجة إليها؛ للمساعدة في الوقاية من غالب أعراض التهيجات أو عالجها، مثل )األلم والتورم في المفصل(. قد يطلب منك طبيبك إجراء فحوصات دم للتأكد من أن الكبد يعمل بشكل طبيعي. األطفال ُعط هذا الدواء لألطفال دون سن 18 ً عاما ألنه لم يتم إثبات سالمته وفعاليته. ال ت ُ األدوية األخرى وأقراص يوكسورات المغلفة ً أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخر َّ ا أو قد تتناول أي أدوية أخرى، بما في ذلك األدوية التي تم الحصول عليها بدون وصفة طبية. ٍ من المواد ًّ من المهم جد ّ ا إخبار طبيبك أو الصيدلي إذا كنت تتناول أدوية تحتوي على أي التالية؛ ألنها قد تتفاعل مع يوكسورات وقد يرغب طبيبك في النظر في التدابير الالزمة: ُستخدم لعالج السرطان(. - مركابتوبورين )ي ُستخدم لتقليل االستجابة المناعية(. - آزاثيوبرين )ي ُستخدم لعالج الربو(. - ثيوفيلين )ي ً أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخر َّ ا أو قد تتناول أي أدوية أخرى. تناول يوكسورات مع الطعام والشراب يجب تناول يوكسورات عن طريق الفم. ويكمن تناوله مع الطعام أو بدونه الحمل والرضاعة الطبيعية ًا ما إذا كان يوكسورات قد يضر بالجنين. ال ينبغي استخدام يوكسورات ليس معروف ًا ما إذا كان يوكسورات ينتقل إلى حليب األم. يجب عدم أثناء الحمل. ليس معروف ِ استخدام يوكسورات إذا كنت ُ مرضعة أو تخططين للرضاعة الطبيعية. ِ إذا كنت حامًاًل ُ أو مرضعة، أو تعتقدين أنك حامل أو تخططين إلنجاب طفل، استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء. القيادة واستخدام اآلالت: يجب أن تدرك أنك قد تعاني من الدوار أو النعاس أو تشوش الرؤية أو التنميل أو اإلحساس بالوخز أثناء العالج، ويجب أال تقود السيارة أو تشغل اآلالت إذا عانيت من ٍ من هذه األعراض. ّ أي ُ تحتوي أقراص يوكسورات المغلفة على الالكتوز: ُ تحتوي أقراص يوكسورات المغلفة على الالكتوز )نوع من السكر(. إذا تم إخبارك بأن ُرجى االتصال بطبيبك قبل تناول هذا الدواء. جسمك ال يتحمل بعض السكريات، ي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احرص دائم ً ا على تناول هذا الدواء تماما كما هو موصوف في هذه النشرة أو كما ً أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا. &bull; الجرعة المعتادة هي قرص واحد يوميًّا. تم وضع عالمة على الجزء الخلفي من عبوة الشرائط تدل على أيام األسبوع لمساعدتك على التحقق من تناول جرعة كل يوم. &bull; يجب أن تؤخذ األقراص عن طريق الفم ويمكن تناولها مع الطعام أو بدونه. النقرس: يوكسورات متوفر في أقراص 40 ملغ، أو 80 ملغ أو 120 ملغ. سيصف لك طبيبك التركيز األنسب لك. واظب على تناول يوكسورات كل يوم حتى عندما ال تعاني من تهيجات أو نوبات النقرس. خط التقسيم في قرص 80 ملغ هو فقط للمساعدة على كسر القرص لتسهيل البلع وليس للتقسيم إلى جرعات متساوية. ُ إذا تناولت أقراص يوكسورات المغلفة أكثر مما يجب في حال تناولت جرعة زائدة غير مقصودة؛ اسأل طبيبك عما يجب فعله أو اتصل بأقرب قسم للحوادث والطوارئ. ُ إذا نسيت تناول أقراص يوكسورات المغلفة إذا فاتتك جرعة من يوكسورات تناولها حالما تتذكرها؛ ما لم يكن قد اقترب وقت تناول جرعتك التالية. في هذه الحالة تجاوز الجرعة التي فاتتك وتناول الجرعة التالية في الوقت المعتاد. ال تتناول جرعة مضاعفة لتعويض الجرعة المنسية. ُ إذا توقفت عن تناول أقراص يوكسورات المغلفة ال تتوقف عن تناول يوكسورات دون مشورة طبيبك حتى لو كنت تشعر بتحسن. إذا توقفت عن تناول يوكسورات فقد تبدأ مستويات حمض اليوريك باالرتفاع، وقد تتفاقم األعراض بسبب تكوين بلورات جديدة من اليورات داخل وحول المفاصل والكليتين. ُّ إذا كانت لديك أي ِ أسئلة أخرى بخصوص استخدام الدواء، استشر طبيبك أو الممرض أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع األدوية قد يسبب هذا الدواء بعض اآلثار الجانبية، على الرغم من أن ذلك ال يحدث مع الجميع. توقف عن تناول هذا الدواء واتصل بطبيبك على الفور أو اذهب إلى أقرب قسم للطوارئ، إذا حدثت اآلثار الجانبية النادرة التالية )التي قد تصيب 1 من كل 1000 شخص(، ألن رد فعل تحسسي خطير قد يتبع ذلك: ً &bull; ردود الفعل التحسسية، فرط ذلك الحساسية تجاه الدواء )انظر أيضا إلى القسم 2 &raquo;تحذيرات واحتياطات&laquo;(. ُهدد الحياة ويتسم بتكوين بثور؛ وتساقط الجلد واألسطح الداخلية &bull; طفح جلدي يمكن أن ي من تجاويف الجسم، مثل: الفم واألعضاء التناسلية؛ وتقرحات مؤلمة في الفم و/ أو األعضاء التناسلية، مصحوبة بالحمى والتهاب الحلق والتعب )متالزمة ستيفنز- جونسون / انحالل البشرة النخري السمي(، أو بتضخم الغدد الليمفاوية، وتضخم الكبد، والتهاب الكبد )حتى فشل الكبد(؛ وزيادة عدد الخاليا البيضاء في الدم )متالزمة رد الفعل الدوائي مع فرط الحمضات واألعراض الجهازية - DRESS( )انظر القسم 2 (. ُ &bull; طفح جلدي متفشي. اآلثار الجانبية الشائعة )قد تصيب 1 من كل 10 أشخاص( هي: &bull; تغيرات في نتائج اختبارات وظائف الكبد. &bull; إسهال. &bull; صداع. &bull; طفح جلدي )بما في ذلك أنواع مختلفة من الطفح الجلدي، يرجى االطالع أدناه تحت أقسام &raquo;غير شائعة&laquo; و &raquo;نادرة&laquo;(. &bull; الغثيان. &bull; زيادة أعراض النقرس. &bull; تورم موضعي بسبب احتباس السوائل في األنسجة )وذمة(. ُ اآلثار الجانبية األخرى التي لم يتم ذكرها أعاله مدرجة أدناه. اآلثار الجانبية غير الشائعة )قد تصيب 1 من كل 100 أشخاص( هي: &bull; انخفاض الشهية وتغير في مستويات السكر في الدم )داء السكري( والذي قد يكون من أعراضه العطش الشديد، وزيادة مستويات الدهون في الدم، وزيادة الوزن. &bull; فقدان الدافع الجنسي. &bull; صعوبة في النوم والنعاس. &bull; الدوار، والتنميل، والوخز، وانخفاض أو تغير باإلحساس )نقص اإلحساس، أو الخزل َ الشقي أو مَذل(، والتغير في حاسة التذوق، وتضاؤل حاسة الشم )ضعف حاسة الشم(. &bull; تغيرات في قيم التخطيط الكهربائي للقلب، وعدم انتظام ضربات القلب أو تسارعها، والشعور بضربات قلبك )خفقان(. &bull; توردات ساخنة أو االحمرار مثل )احمرار الوجه أو الرقبة(، وزيادة ضغط الدم. &bull; السعال، وضيق في التنفس، وشعور بعدم الراحة أو ألم بالصدر، والتهاب بمجرى األنف و / أو الحلق )التهاب الجهاز التنفسي العلوي(، والتهاب الشعب الهوائية. &bull; جفاف الفم، وألم في البطن / عدم راحة أو غازات، وحرقة في المعدة / عسر هضم، واإلمساك، زيادة تكرار التبرز، والقيء، وشعور بعدم راحة في المعدة. &bull; الحكة، والشرى، والتهاب الجلد، وتغير لون الجلد، وبقع حمراء أو أرجوانية صغيرة على الجلد، وبقع حمراء صغيرة مسطحة على الجلد، ومنطقة مسطحة حمراء على ُ الجلد مغطاة بنتوءات صغيرة متجمعة، وطفح جلدي، ومناطق احمرار وبقع على الجلد، وأنواع أخرى من األمراض الجلدية. &bull; تقلصات العضالت، أو ضعف العضالت، أو ألم / وجع في العضالت / المفاصل، أو ًا بألم، وتورم التهاب كيسي، أو التهاب المفاصل )التهاب المفاصل عادة ما يكون مصحوب و / أو تصلب(، ألم في األطراف، أو ألم في الظهر، أو تشنج عضلي. &bull; دم في البول، تبول متكرر بشكل غير طبيعي، تغيرنتائج قيم فحص البول )زيادة مستوى البروتين في البول(، انخفاض وظائف الكلى الطبيعية. &bull; التعب، تورم موضعي نتيجة لعودة السوائل إلى األنسجة )وذمة( وألم بالصدر، وعدم راحة بالصدر. َّ ِّ حصي الصفراوي(. &bull; حصوات في المرارة أو القنوات الصفراوية )الت &bull; زيادة في مستوى الهرمون المستحث للغدة الدرقية في الدم. &bull; تغيرات في كيمياء الدم أو كمية خاليا الدم أو الصفائح الدموية )اختالل في نتائج إختبار فحوصات الدم(. &bull; حصوات الكلى. &bull; صعوبات االنتصاب. األثار الجانبية النادرة )قد تصيب 1 من كل 1000 شخص( هي: &bull; تلف العضالت؛ وهي حالة يمكن أن تكون خطيرة في حاالت نادرة. قد يسبب مشاكل في العضالت، وخاصة إذا شعرت في نفس الوقت بتوعك أو ارتفاع في درجة الحرارة، ً فقد يكون ناتجا عن انهيار عضلي غير طبيعي. اتصل بطبيبك على الفور إذا كنت تعاني من ألم أو ليونة أو ضعف في العضالت. &bull; تورم شديد في الطبقات العميقة من الجلد، خاصة حول الشفتين أو العينين أو األعضاء التناسلية أو اليدين أو القدمين أو اللسان، مع احتمال حدوث صعوبة مفاجئة في التنفس. &bull; حمى شديدة مع طفح جلدي شبيه بالحصبة، وتضخم في الغدد الليمفاوية، وتضخم الكبد، والتهاب الكبد )حتى فشل الكبد(، وزيادة عدد خاليا الدم البيضاء في الدم )كثرة الكريات البيض، مع أو بدون فرط الحمضات(. ُ &bull; احمرار الجلد )ح َم َامى(، وطفح جلدي بأنواع مختلفة، على سبيل المثال )مثير للحكة، مصحوب ببقع بيضاء، مع بثور، مع بثور تحتوي على صديد، تقشر الجلد، طفح ُ جلدي شبيه بالحصبة(، وح َم َامى منتشرة، ونخر، وانحالل فقاعي للبشرة واألغشية المخاطية، مما يؤدي إلى تقشير وإنتان محتمل )متالزمة ستيفنز جونسون / انحالل البشرة النخري السمي(. &bull; العصبية. &bull; الشعور بالعطش. &bull; طنين األذن. &bull; تشوش الرؤية وتغير في الرؤية. &bull; تساقط الشعر. &bull; تقرح الفم. &bull; التهاب البنكرياس: األعراض الشائعة هي ألم البطن والغثيان والقيء &bull; زيادة التعرق. &bull; انخفاض الوزن، وزيادة الشهية، وفقدان الشهية غير المنضبط )فقدان الشهية(. &bull; تصلب العضالت و / أو المفاصل. &bull; انخفاض غير طبيعي في عدد خاليا الدم )خاليا الدم البيضاء أو الحمراء أو الصفائح الدموية(. ُ &bull; الحاجة الملحة للتبول. &bull; تغيرات أو نقصان في كمية البول بسبب التهاب الكلى )التهاب الكلية األنبوبي الخاللي الحاد(. &bull; التهاب الكبد )التهاب الكبد الوبائي(. &bull; اصفرار الجلد )اليرقان(. &bull; تلف الكبد. &bull; زيادة مستوى فوسفوكيناز الكرياتين في الدم )مؤشر لتلف العضالت(. &bull; الموت القلبي المفاجئ. اإلبالغ عن اآلثار الجانبية ٍ ِ من اآلثار الجانبية، استشر طبيبك أو الممرض أو الصيدلي. ويشمل ّ إذا تعرضت ألي َّ هذا أي ُ آثار جانبية محتملة غير م َدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ هذا الدواء بعيدا عن مرأى ومتناول األطفال. &bull; ي &bull; يجب عدم استخدام الدواء بعد تاريخ االنتهاء الموضح على الكرتونة والعبوة بعد كلمة EXP. يشير تاريخ االنتهاء إلى اليوم األخير من ذلك الشهر. ُحفظ في درجة حرارة أقل من 30 درجة مئوية. &bull; ي ِ أدوية في مياه الصرف الصحي أو إلقائها في القمامة. اسأل ّ &bull; يجب عدم التخلص من أي ُ ْد بحاجة إلى استخدامها؛ ألن هذه الصيدلي عن كيفية التخلص من األدوية التي لم تَع التدابير تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي: فيبوكسوستات المكونات األخرى هي: السليلوز الجريزوفولفين، والالكتوز مونوهيدرات، وكروسكارميلوز الصوديوم، وهيدروكسي بروبيل السيللوز، وثاني أكسيد السيليكون الغرواني، وأوبادري 2 األصفر وستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>- أقراص 40 ُ ملغ الم ُ غلفة: هي أقراص صفراء مستديرة محدبة الوجهين ملبسة بالفم محفور عليها &raquo;1C &raquo;من جانب ومستوية من الجانب اآلخر. - أقراص 80 ُ ملغ المغلفة: هي أقراص صفراء على شكل كبسولة محدبة الوجهين ُ المغلفة، وهي مسطحة من جانب ويوجد بها خط الكسر بالجانب اآلخر. - أقراص 120 ُ ملغ المغلفة: هي أقراص صفراء على شكل كبسولة محدبة الوجهين ُ المغلفة محفور عليها &raquo;64C &raquo;من جانب و&laquo;/&laquo; من الجانب اآلخر. تتوافر أقراص يوكسورات في عبوات 40 ملغ 3 شرائط )10 أقراص / شريط( و 80 ملغ 2 شرائط )14 أقراص / شريط( و 120 ملغ 2 شرائط )14 أقراص / شريط(.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة الشرق األوسط للصناعات الدوائية المحدودة. )أفالون فارما( ص.ب. 4180 الرياض 11491 المدينة الصناعية الثانية، الرياض، المملكة العربية السعودية هاتف 3427 265 &ndash; 3948 265 )11( 966 00 فاكس 4723 265 )11( 966 0</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في 11-2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Uxorate 120 mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Uxorate 120 mg: each tablet contains 120 mg of febuxostat.
Excipient(s) with known effects:
Uxorate 120 mg: each tablet contains 114.75mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablets.
• Uxorate 120 mg film coated tablets are: Yellow, Capsule shaped, biconvex, film coated
tablet debossed with “C64” on one side and ‘/’ on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology Gout: The recommended oral dose of Uxorate is 80 mg once daily without regard to food. If serum uric acid is &gt; 6 mg/dL (357 &micro;mol/L) after 2-4 weeks, UXORATE 120 mg once daily may be considered. Uxorate works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks. The therapeutic target is to decrease and maintain serum uric acid below 6 mg/dL (357&mu;mol/L). Gout flare prophylaxis of at least 6 months is recommended (see section 4.4). Special populations Renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance &lt;30 mL/min, see section 5.2). Hepatic impairment Gout: The recommended dose in patients with mild hepatic impairment is 80 mg. Limited information is available in patients with moderate hepatic impairment. The efficacy and safety of febuxostat has not been studied in patients with severe hepatic impairment (Child Pugh Class C). 2 Elderly No dose adjustment is required in the elderly (see section 5.2). Children and adolescents As there has been no experience in children and adolescents, the use of febuxostat in such patients is not recommended Organ transplant recipients As there has been no experience in organ transplant recipients, the use of febuxostat in such patients is not recommended (see section 5.1). Method of administration Oral use Uxorate should be taken by mouth and can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see also section 
4.8).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cardio-vascular disorders Treatment with febuxostat in patients with ischaemic heart disease or congestive heart failure is not recommended. A higher rate of cardiovascular thromboembolic events was observed in patients treated with febuxostat than allopurinol in clinical trials. Monitor for signs and symptoms of MI and stroke. (see section 4.8). Acute gouty attacks (gout flare) Febuxostat treatment should not be started until an acute attack of gout has completely subsided. Gout flares may occur during initiation of treatment due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits (see sections 4.8 and 5.1). At treatment initiation with febuxostat flare prophylaxis for at least 6 months with an NSAID or colchicine is recommended (see section 4.2). If a gout flare occurs during febuxostat treatment, it should not be discontinued. The gout flare should be managed concurrently as appropriate for the individual patient. Continuous treatment with febuxostat decreases frequency and intensity of gout flares. Xanthine deposition In patients in whom the rate of urate formation is greatly increased (e.g. malignant disease and its treatment, Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine could, in rare cases, rise sufficiently to allow deposition in the urinary tract.As there has been no experience with febuxostat, its use in these populations is not recommended. Mercaptopurine/azathioprine Febuxostat use is not recommended in patients concomitantly treated with mercaptopurine/azathioprine (see section 4.5) Theophylline Febuxostat should be used with caution in patients concomitantly treated with theophylline and theophylline levels should be monitored in patients starting febuxostat therapy (see section 4.5). 3 Liver disorders During the combined phase 3 clinical studies, mild liver function test abnormalities were observed in patients treated with febuxostat (5.0%). Liver function test is recommended prior to the initiation of therapy with febuxostat and periodically thereafter based on clinical judgment (see section 5.1). Thyroid disorders Increased TSH values (&gt;5.5 &micro;IU/mL) were observed in patients on long-term treatment with febuxostat (5.5%) in the long-term open label extension studies. Caution is required when febuxostat is used in patients with alteration of thyroid function (see section 5.1). Lactose Febuxostat tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mercaptopurine/azathioprine Although interaction studies with febuxostat have not been performed, inhibition of xanthine oxidase (XO) is known to result in an increase in mercaptopurine or azathioprine levels. On the basis of the mechanism of action of febuxostat on XO inhibition concomitant use is not recommended. Drug interaction studies of febuxostat with cytotoxic chemotherapy have not been conducted. No data is available regarding the safety of febuxostat during cytotoxic therapy. Theophylline Although interaction studies have not been performed with febuxostat, inhibition of XO may cause an increase in the theophylline level (inhibition of the metabolism of theophylline has been reported with other XO inhibitors). Hence caution is advised if these active substances are given concomitantly, and theophylline levels should be monitored in patients starting febuxostat therapy. Naproxen and other inhibitors of glucuronidation Febuxostat metabolism depends on Uridine Glucuronosyl Transferase (UGT) enzymes. Medicinal products that inhibit glucuronidation, such as NSAIDs and probenecid, could in theory affect the elimination of febuxostat. In healthy subject&rsquo;s concomitant use of febuxostat and naproxen 250mg twice daily was associated with an increase in febuxostat exposure (Cmax 28%, AUC 41% and t1/2 26%). In clinical studies the use of naproxen or other NSAIDs/Cox-2 inhibitors were not related to any clinically significant increase in adverse events. Febuxostat can be co-administered with naproxen with no dose adjustment of febuxostat or naproxen being necessary. Inducers of glucuronidation Potent inducers of UGT enzymes might possibly lead to increased metabolism and decreased efficacy of febuxostat. Monitoring of serum uric acid is therefore recommended 1-2 weeks after start of treatment with a potent inducer of glucuronidation. Conversely, cessation of treatment of an inducer might lead to increased plasma levels of febuxostat. Colchicine/indometacin/hydrochlorothiazide/warfarin Febuxostat can be co-administered with colchicine or indomethacin with no dose adjustment of febuxostat or the co-administered active substance being necessary. No dose adjustment is necessary for febuxostat when administered with hydrochlorothiazide. 4 No dose adjustment is necessary for warfarin when administered with febuxostat. Administration of febuxostat (80 mg or 120 mg once daily) with warfarin had no effect on the pharmacokinetics of warfarin in healthy subjects. INR and Factor VII activity were also not affected by the co-administration of febuxostat. Desipramine/CYP2D6 substrates Febuxostat was shown to be a weak inhibitor of CYP2D6 in vitro. In a study in healthy subjects, 120 mg UXORATE QD resulted in a mean 22% increase in AUC of desipramine, a CYP2D6 substrate indicating a potential weak inhibitory effect of febuxostat on the CYP2D6 enzyme in vivo. Thus, co-administration of febuxostat with other CYP2D6 substrates is not expected to require any dose adjustment for those compounds. Antacids Concomitant ingestion of an antacid containing magnesium hydroxide and aluminium hydroxide has been shown to delay absorption of febuxostat (approximately 1 hour) and to cause a 32% decrease in Cmax, but no significant change in AUC was observed. Therefore, febuxostat may be taken without regard to antacid use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy Data on a very limited number of exposed pregnancies have not indicated any adverse effects of febuxostat on pregnancy or on the health of the foetus/newborn child. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, or parturition (see section 5.3). The potential risk for human is unknown. Febuxostat should not be used during pregnancy. Breast-feeding It is unknown whether febuxostat is excreted in human breast milk. Animal studies have shown excretion of this active substance in breast milk and an impaired development of suckling pups. A risk to a suckling infant cannot be excluded. Febuxostat should not be used while breastfeeding. Fertility In animals, reproduction studies up to 48 mg/kg/day showed no dose-dependent adverse effects on fertility (see section 5.3). The effect of Uxorate on human fertility is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Somnolence, dizziness, paraesthesia and blurred vision have been reported with the use of Febuxostat. Patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that UXORATE does not adversely affect performance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A total of 4,072 subjects received at least one dose of FEBUXOSTAT (10 mg &ndash; 300 mg) in clinical studies. Combined phase 3 randomised controlled studies In randomised controlled phase 3 clinical studies, &gt;2,500 patients have been treated with 40 mg to 120 mg (1513 subjects enrolled in a 26-week study (CONFIRMS), 536 subjects enrolled in a 28-week study (APEX) and 507 subjects enrolled in a 52-weeks study (FACT)). The treatment-related events (ADRs) were mostly. mild or moderate in severity. The most commonly reported ADRs (investigator assessment) are liver function abnormalities (5.0%), diarrhoea (2.7%), nausea (1.3%), headache (1.2%), rash (1.2 %). 5 Gout flares were also commonly observed soon after the start of treatment and during the first months. Thereafter, the frequency of gout flare decreases in a time-dependent manner. As with other urate lowering medicinal products, gout flare prophylaxis is recommended (see section 4.2 and 4.4). A numerical greater incidence of investigator-reported cardiovascular APTC events (defined endpoints from the Anti-Platelet Trialists&#39; Collaboration (APTC) including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) was observed in the febuxostat total group compared to the allopurinol group in the APEX and FACT studies (1.3 vs. 0.3 events per 100 PYs), but not in the CONFIRMS study. The incidence of investigator-reported cardiovascular APTC events in the combined Phase III studies (APEX, FACT and CONFIRMS studies) was 0.7 vs. 0.6 events per 100 PYs. In the long-term extension studies the incidences of investigator-reported APTC events were 1.2 and 0.6 events per 100 PYs for febuxostat and allopurinol, respectively. No statistically significant differences were found and no causal relationship with febuxostat was established. Identified risk factors among these patients were a medical history of atherosclerotic disease and/or myocardial infarction, or of congestive heart failure. Common (1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100) and rare ( 1/10,000 to &lt; 1/1000) adverse reactions suspected (investigator assessment) to be drug related occurring in patients treated with 40 mg to 120 mg febuxostat and reported more than once in the total febuxostat treatment group are listed below. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. Table 1: Adverse reactions in combined phase 3, long-term extension studies and post-marketing experience in gout patients Blood and lymphatic system disorders Rare Pancytopenia, Metabolism and nutrition disorders Common*** Gout flares Uncommon decrease appetite, Rare Weight increase /decrease, increase appetite, anorexia, hyperlipidemia Psychiatric disorders Uncommon Libido decreased, insomnia Rare Nervousness Nervous system disorders Common Headache Uncommon Dizziness, paraesthesia, hemiparesis, somnolence, altered taste, hypoaesthesia, Ear and labyrinth disorders Rare Tinnitus Cardiac disorders Uncommon Atrial fibrillation, palpitations, ECG abnormal, Vascular disorders Uncommon Hypertension, flushing, hot flush, Respiratory system disorders Uncommon Dyspnoea, upper respiratory tract infection, Gastrointestinal disorders Common Diarrhoea**, nausea Uncommon 6 Abdominal pain, gastro-oesophageal reflux disease, vomiting, dry mouth, dyspepsia, constipation, frequent stools, flatulence, gastrointestinal discomfort Rare Pancreatitis, mouth ulceration Hepato-biliary disorders Common Liver function abnormalities** Skin and subcutaneous tissue disorders Common Rash Uncommon Dermatitis, urticaria, pruritus, Rare alopecia, hyperhidrosis Musculoskeletal and connective tissue disorders Uncommon Arthralgia, myalgia, musculoskeletal pain, muscle weakness, muscle spasm, Rare arthritis, joint stiffness, musculoskeletal stiffness Renal and urinary disorders Uncommon Renal failure, nephrolithiasis, haematuria, pollakiuria Rare micturition urgency Reproductive system and breast disorder Rare Erectile dysfunction General disorders and administration site conditions Uncommon Fatigue, Oedema, chest pain, chest discomfort Rare Thirst Investigations Uncommon Blood amylase increase, platelet count decrease, WBC decrease, lymphocyte count decrease, blood creatine increase, blood creatinine increase, haemoglobin decrease, blood urea increase, blood triglycerides increase, blood cholesterol increase, haematocritic decrease, blood lactate dehydrogenase increased, blood potassium increase Rare Blood glucose increased, activated partial thromboplastin time prolonged, red blood cell count decrease, blood alkaline phosphatase increase, blood creatine phosphokinase increase* ** Treatment-emergent non-infective diarrhoea and abnormal liver function tests in the combined Phase 3 studies are more frequent in patients concomitantly treated with colchicine. *** See section 5.1 for incidences of gout flares in the individual Phase 3 randomized controlled studies. Long-term open label extension studies In the long-term open label extension studies (1143 patients), the number of patients treated with febuxostat 40 mg/80 mg/120 mg up to 1 year was 909, up to 2 years was 781, up to 3 years was 348, and up to 4 and 5 years was 60. The treatment-related events reported during the long-term extension studies were similar to those reported in the Phase 3 studies (see Table 1). The most commonly reported treatment-related events (investigator assessment) are: liver function abnormalities, diarrhoea, headache, rash, hypertension, oedema. 7 The following treatment-related events were reported more than once in the total febuxostat treatment group and were reported as uncommon in patients taking febuxostat 40 mg/80 mg/120 mg in long-term extension studies (up to 5 years, &gt;2,660 Patient-years of exposure). These treatment-related events were either not reported or reported at a lower frequency for these doses, in the combined Phase 3 studies: abdominal distension, cholelithiasis, bronchitis, weight increase, blood creatine increase, diabetes mellitus, hyperlipidaemia, arthritis, muscle tightness, hyposmia, hemiparesis, cough, skin discolouration, skin lesion, bursitis, proteinuria, petechiae, erectile dysfunction, blood potassium increase, blood TSH increase, lymphocyte count decreased, WBC decrease. Adverse reactions from spontaneous reporting There have been post-marketing reports of rare serious rashes, generalised skin rashes and severe hypersensitivity reactions. In most cases, these reactions occurred during the first month of therapy with febuxostat. Some of these patients, but not all, reported previous hypersensitivity to allopurinol. To Report any side effects: Saudi Arabia:&nbsp;The National Pharmacovigilance Centre (NPC) o SFDA call center: 19999 o E-mail: npc.drug@sfda.gov.sa o Website: https://ade.sfda.gov.sa</p><p>Other GCC States:&nbsp;- Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported. Patients with an overdose should be managed by symptomatic and supportive care.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anatomical Therapeutical Chemical (ATC): preparations inhibiting uric acid production, ATC code: M04AA03 Mechanism of action Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine xanthine uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO. Febuxostat is a potent, non-purine selective inhibitor of XO (NP-SIXO) with an in vitro inhibition Ki value less than one nanomolar. Febuxostat has been shown to potently inhibit both the oxidized and reduced forms of XO. At therapeutic concentrations febuxostat does not inhibit other enzymes involved in purine or pyrimidine metabolism, namely, guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine nucleoside phosphorylase. The National Pharmacovigilance Centre (NPC) o SFDA call center: 19999 o E-mail: npc.drug@sfda.gov.sa o Website: https://ade.sfda.gov.sa 8 Clinical efficacy and safety Gout The efficacy of UXORATE was demonstrated in three Phase 3 pivotal studies (the two pivotal APEX and FACT studies, and the additional CONFIRMS study described below) that were conducted in 4101 patients with hyperuricaemia and gout. In each phase 3 pivotal study, UXORATE demonstrated superior ability to lower and maintain serum uric acid levels compared to allopurinol. The primary efficacy endpoint in the APEX and FACT studies was the proportion of patients whose last 3 monthly serum uric acid levels were &lt; 6.0 mg/dL (357 &micro;mol/L). In the additional phase 3 CONFIRMS study, for which results became available after the marketing authorisation for UXORATE was first issued, the primary efficacy endpoint was the proportion of patients whose serum urate level was &lt; 6.0 mg/dL at the final visit. No patients with organ transplant have been included in these studies (see section 4.2). APEX Study: The Allopurinol and Placebo-Controlled Efficacy Study of Febuxostat (APEX) was a Phase 3, randomized, double-blind, multicenter, 28-week study. One thousand and seventy-two (1072) patients were randomized: placebo (n=134), UXORATE 80 mg QD (n=267), UXORATE 120 mg QD (n=269), UXORATE 240 mg QD (n=134) or allopurinol (300 mg QD [n=258] for patients with a baseline serum creatinine &le;1.5 mg/dL or 100 mg QD [n=10] for patients with a baseline serum creatinine &gt;1.5 mg/dL and &le;2.0 mg/dL). Two hundred and forty mg febuxostat (2 times the recommended highest dose) was used as a safety evaluation dose. The APEX study showed statistically significant superiority of both the UXORATE 80 mg QD and the UXORATE 120 mg QD treatment arms versus the conventionally used doses of allopurinol 300 mg (n = 258) /100 mg (n = 10) treatment arm in reducing the sUA below 6 mg/dL (357 &micro;mol/L) (see Table 2 and Figure 1). FACT Study: The Febuxostat Allopurinol Controlled Trial (FACT) Study was a Phase 3, randomized, double-blind, multicenter, 52-week study. Seven hundred sixty (760) patients were randomized: UXORATE 80 mg QD (n=256), UXORATE 120 mg QD (n=251), or allopurinol 300 mg QD (n=253). The FACT study showed the statistically significant superiority of both UXORATE 80 mg and UXORATE 120 mg QD treatment arms versus the conventionally used dose of allopurinol 300 mg treatment arm in reducing and maintaining sUA below 6 mg/dL (357 &micro;mol/L). Table 2 summarises the primary efficacy endpoint results: Table 2 Proportion of Patients with Serum Uric Acid Levels 1.5 and &le;2.0 mg/dL) or 300 mg QD (n=509) were pooled for analyses. * p &lt; 0.001 vs allopurinol, # p &lt; 0.001 vs 80 mg 9 The ability of UXORATE to lower serum uric acid levels was prompt and persistent. Reduction in serum uric acid level to 1.5 and &lt; 2.0 mg/dL were dosed with 100 mg QD. (10 patients out of 268 in APEX study). 240 mg febuxostat was used to evaluate the safety of febuxostat at twice the recommended highest dose. CONFIRMS Study: The CONFIRMS study was a Phase 3, randomized, controlled, 26-week study to evaluate the safety and efficacy of febuxostat 40 mg and 80 mg, in comparison with allopurinol 300 mg or 200 mg, in patients with gout and hyperuricaemia. Two thousand and two hundred-sixty nine (2269) patients were randomized: UXORATE 40 mg QD (n=757), UXORATE 80 mg QD (n=756), or allopurinol 300/200 mg QD (n=756). At least 65% of the patients had mild-moderate renal impairment (with creatinine clearance of 30-89 mL/min). Prophylaxis against gout flares was obligatory over the 26-week period. The proportion of patients with serum urate levels of &lt; 6.0 mg/dL (357 &micro;mol/L) at the final visit, was 45% for 40 mg febuxostat, 67% for febuxostat 80 mg and 42% for allopurinol 300/200 mg, respectively. Primary endpoint in the sub-group of patients with renal impairment The APEX Study evaluated efficacy in 40 patients with renal impairment (i.e., baseline serum creatinine &gt; 1.5 mg/dL and &le;2.0 mg/dL). For renally impaired subjects who were randomized to allopurinol, the dose was capped at 100 mg QD. UXORATE achieved the primary efficacy endpoint in 44% (80 mg QD), 45% (120 mg QD), and 60% (240 mg QD) of patients compared to 0% in the allopurinol 100 mg QD and placebo groups. There were no clinically significant differences in the percent decrease in serum uric acid concentration in healthy subjects irrespective of their renal function (58% in the normal renal function group and 55% in the severe renal dysfunction group). An analysis in patients with gout and renal impairment was prospectively defined in the CONFIRMS study and showed that febuxostat was significantly more efficacious in lowering serum urate levels to &lt; 6 mg/dL compared to allopurinol 300 mg/200 mg in patients who had gout with mild to moderate renal impairment (65% of patients studied). 10 Primary endpoint in the subgroup of patients with sUA &ge; 10 mg/dL Approximately 40% of patients (combined APEX and FACT) had a baseline sUA of &ge; 10 mg/dL. In this subgroup UXORATE achieved the primary efficacy endpoint (sUA &lt; 6.0 mg/dL at the last 3 visits) in 41% (80 mg QD), 48% (120 mg QD), and 66% (240 mg QD) of patients compared to 9% in the allopurinol 300 mg/100 mg QD and 0 % in the placebo groups. In the CONFIRMS study, the proportion of patients achieving the primary efficacy endpoint (sUA &lt; 6.0 mg/dL at the final visit) for patients with a baseline serum urate level of &ge; 10 mg/dL treated with febuxostat 40 mg QD was 27% (66/249), with febuxostat 80 mg QD 49% (125/254) and with allopurinol 300 mg/200 mg QD 31% (72/230), respectively. Clinical Outcomes: proportion of patients requiring treatment for a gout flare APEX study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36%) treatment group required treatment for gout flare compared to febuxostat 80 mg (28%), allopurinol 300 mg (23%) and placebo (20%). Flares increased following the prophylaxis period and gradually decreased over time. Between 46% and 55% of subjects received treatment for gout flares from Week 8 and Week 28. Gout flares during the last 4 weeks of the study (Weeks 24-28) were observed in 15% (febuxostat 80, 120 mg), 14% (allopurinol 300 mg) and 20% (placebo) of subjects. FACT study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg (36%) treatment group required treatment for a gout flare compared to both the febuxostat 80 mg (22%) and allopurinol 300 mg (21%) treatment groups. After the 8-week prophylaxis period, the incidences of flares increased and gradually decreased over time (64% and 70% of subjects received treatment for gout flares from Week 8-52). Gout flares during the last 4 weeks of the study (Weeks 49- 52) were observed in 6-8% (febuxostat 80 mg, 120 mg) and 11% (allopurinol 300 mg) of subjects. The proportion of subjects requiring treatment for a gout flare (APEX and FACT Study) was numerically lower in the groups that achieved an average post-baseline serum urate level 6.0 mg/dL were withdrawn. Serum urate levels were maintained over time (i.e., 91% and 93% of patients on initial treatment with febuxostat 80 mg and 120 mg, respectively, had sUA 5.5 &micro;IU/mL) were observed in patients on long-term treatment with febuxostat (5.5%) and patients with allopurinol (5.8%) in the long-term open label extension studies (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In healthy subjects, maximum plasma concentrations (Cmax) and area under the plasma concentration time curve (AUC) of febuxostat increased in a dose proportional manner following single and multiple doses of 10 mg to 120 mg. For doses between 120 mg and 300 mg, a greater than dose proportional increase in AUC is observed for febuxostat. There is no appreciable accumulation when doses of 10 mg to 240 mg are administered every 24 hours. Febuxostat has an apparent mean terminal elimination halflife (t1/2) of approximately 5 to 8 hours. Population pharmacokinetic/pharmacodynamic analyses were conducted in 211 patients with hyperuricaemia and gout, treated with UXORATE 40-240 mg QD. In general, febuxostat pharmacokinetic parameters estimated by these analyses are consistent with those obtained from healthy subjects, indicating that healthy subjects are representative for pharmacokinetic/pharmacodynamic assessment in the patient population with gout. Absorption Febuxostat is rapidly (tmax of 1.0-1.5 h) and well absorbed (at least 84%). After single or multiple oral 80 and 120 mg once daily doses, Cmax is approximately 2.8-3.2 &micro;g/mL, and 5.0-5.3 &micro;g/mL, respectively. Absolute bioavailability of the febuxostat tablet formulation has not been studied. Following multiple oral 80 mg once daily doses or a single 120 mg dose with a high fat meal, there was a 49% and 38% decrease in Cmax and a 18% and 16% decrease in AUC, respectively. However, no clinically significant change in the percent decrease in serum uric acid concentration was observed where tested (80 mg multiple dose). Thus, UXORATE may be taken without regard to food. Distribution The apparent steady state volume of distribution (Vss/F) of febuxostat ranges from 29 to 75 L after oral doses of 10-300 mg. The plasma protein binding of febuxostat is approximately 99.2%, (primarily to albumin), and is constant over the concentration range achieved with 80 and 120 mg doses. Plasma protein binding of the active metabolites ranges from about 82% to 91%. Biotransformation Febuxostat is extensively metabolized by conjugation via uridine diphosphate glucuronosyltransferase (UDPGT) enzyme system and oxidation via the cytochrome P450 (CYP) system. Four pharmacologically active hydroxyl metabolites have been identified, of which three occur in plasma of humans. In vitro studies with human liver microsomes showed that those oxidative metabolites were formed primarily by CYP1A1, CYP1A2, CYP2C8 or CYP2C9 and febuxostat glucuronide was formed mainly by UGT 1A1, 1A8, and 1A9. Elimination Febuxostat is eliminated by both hepatic and renal pathways. Following an 80 mg oral dose of 14Clabeled febuxostat, approximately 49% of the dose was recovered in the urine as unchanged febuxostat (3%), the acyl glucuronide of the active substance (30%), its known oxidative metabolites and their conjugates (13%), and other unknown metabolites (3%). In addition to the urinary excretion, approximately 45% of the dose was recovered in the faeces as the unchanged febuxostat (12%), the 12 acyl glucuronide of the active substance (1%), its known oxidative metabolites and their conjugates (25%), and other unknown metabolites (7%). Renal impairment Following multiple doses of 80 mg of UXORATE in patients with mild, moderate or severe renal impairment, the Cmax of febuxostat did not change, relative to subjects with normal renal function. The mean total AUC of febuxostat increased by approximately 1.8-fold from 7.5 &mu;g h/mL in the normal renal function group to 13.2 &mu;g.h/mL in the severe renal dysfunction group. The Cmax and AUC of active metabolites increased up to 2- and 4-fold, respectively. However, no dose adjustment is necessary in patients with mild or moderate renal impairment. Hepatic impairment Following multiple doses of 80 mg of UXORATE in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, the Cmax and AUC of febuxostat and its metabolites did not change significantly compared to subjects with normal hepatic function. No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C). Age There were no significant changes observed in AUC of febuxostat or its metabolites following multiple oral doses of UXORATE in elderly as compared to younger healthy subjects. Gender Following multiple oral doses of UXORATE , the Cmax and AUC were 24% and 12% higher in females than in males, respectively. However, weight-corrected Cmax and AUC were similar between the genders. No dose adjustment is needed based on gender.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects in non-clinical studies were generally observed at exposures in excess of the maximum human exposure. Carcinogenesis, mutagenesis, impairment of fertility In male rats, a statistically significant increase in urinary bladder tumours (transitional cell papilloma and carcinoma) was found only in association with xanthine calculi in the high dose group, at approximately 11 times human exposure. There was no significant increase in any other tumour type in either male or female mice or rats. These findings are considered a consequence of specific purine metabolism and urine composition and of no relevance to clinical use. A standard battery of test for genotoxicity did not reveal any biologically relevant genotoxic effects for febuxostat. Febuxostat at oral doses up to 48 mg/kg/day was found to have no effect on fertility and reproductive performance of male and female rats. There was no evidence of impaired fertility, teratogenic effects, or harm to the foetus due to febuxostat. There was high dose maternal toxicity accompanied by a reduction in weaning index and reduced development of offspring in rats at approximately 4.3 times human exposure. Teratology studies, performed in pregnant rats at approximately 4.3 times and pregnant rabbits at approximately 13 times human exposure did not reveal any teratogenic effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core: Lactose monohydrate ,Microcrystalline cellulose ,Hydroxypropyl cellulose ,Croscarmellose Sodium ,Colloidal silicon dioxide &amp; Magnesium Stearate. 13 Tablet coating:Opadry II Yellow (85F42129) containing :Polyvinyl alcohol, Titanium dioxide, Macrogol, Talc and yellow iron oxide non-irr.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C This medicinal product does not require any special temperature storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The 120 mg tablets are packaged in Clear PVC / Aclar/Aluminum blister packs of 28 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Middle East Pharmaceutical Industries Co. Ltd (Avalon-Pharma)
2nd industrial City, P.O.Box 4180 Riyadh 11491, Kingdom of Saudi Arabia
Tel: 920010564, Fax: +966 (11) 2654723
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11-2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>